Veracyte Inc. (VCYT) and Aquestive Therapeutics Inc. (NASDAQ:AQST) Comparison side by side

Both Veracyte Inc. (NASDAQ:VCYT) and Aquestive Therapeutics Inc. (NASDAQ:AQST) are each other?s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Veracyte Inc. 92.01M 8.88 23.00M -0.64 0.00
Aquestive Therapeutics Inc. 62.80M 3.05 58.10M -2.81 0.00

In table 1 we can see Veracyte Inc. and Aquestive Therapeutics Inc.’s top-line revenue, earnings per share and valuation.


Table 2 has Veracyte Inc. and Aquestive Therapeutics Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Veracyte Inc. -25.00% -42.8% -24.4%
Aquestive Therapeutics Inc. -92.52% 0% 0%


The current Quick Ratio of Veracyte Inc. is 7.2 while its Current Ratio is 7.4. Meanwhile, Aquestive Therapeutics Inc. has a Current Ratio of 3.6 while its Quick Ratio is 3.4. Veracyte Inc. is better positioned to pay off its short-term and long-term debts than Aquestive Therapeutics Inc.

Analyst Ratings

In next table is shown Veracyte Inc. and Aquestive Therapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Veracyte Inc. 0 1 1 2.50
Aquestive Therapeutics Inc. 0 0 0 0.00

Veracyte Inc.?s upside potential currently stands at 15.75% and an $23 consensus price target.

Insider & Institutional Ownership

Veracyte Inc. and Aquestive Therapeutics Inc. has shares owned by institutional investors as follows: 97.3% and 67.5%. 0.3% are Veracyte Inc.’s share owned by insiders. Comparatively, insiders own roughly 8.2% of Aquestive Therapeutics Inc.?s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Veracyte Inc. 5.23% 13.91% 65.23% 69.14% 249.41% 64.71%
Aquestive Therapeutics Inc. -0.56% 16.48% -20.22% -57.75% 0% 13.33%

For the past year Veracyte Inc. has stronger performance than Aquestive Therapeutics Inc.


On 9 of the 11 factors Veracyte Inc. beats Aquestive Therapeutics Inc.

Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company’s products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates that are in development comprise AQST-203, a buccally, an administered soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; AQST-120, an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy; and AQST-117, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's development products also include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; AQST-305, a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors; APL-130277, a sublingual film formulation of apomorphine to treat episodic off-periods in Parkinson's disease; AQST-119, an oral soluble film formulation of tadalafil to treat erectile dysfunction; and AQST-306, a film formulation of edaravone. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.